CareFusion expands Codonics partnership; Health Affairs weighs in on med tech innovation;

@FierceMedDev: ICYMI yesterday: Biosensors Japan's PhIII trial of drug eluting has enrolled patients. Report | Follow @FierceMedDev

@VarunSaxena2: Endoscopes linked to spread of deadly drug-resistant bacteria in hospitals. Story | Follow @VarunSaxena2

@EmilyWFierce: Patient groups still think ViiV is tops, with Novo and AbbVie close behind. FiercePharmaMarketing article | Follow @EmilyWFierce

> CareFusion ($CFN) has expanded a partnership with Codonics to develop synchronized formulary management for the operating room. Release

> Bayer MaterialScience has introduced a new material for use in wearable medical devices, Makroblend M525 polycarbonate/polyester blend resin. It's expected to be durable even with the use of body lotions, disinfectants and other chemicals. Release

> The journal Health Affairs has published a series of recommendations for how to improve innovation in med tech. They include accelerated evaluation of breakthrough products by the FDA and the Centers for Medicare and Medicaid Services (CMS), reimbursement by CMS for innovative products and reform to reduce the industry's tax burden. Article

Biotech News

@FierceBiotech: Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager. Report | Follow @FierceBiotech

@JohnCFierce: I think it's smart of Sanofi to buy into new tech and let the partner lead on innovation. Good model for pharma, which is bad at innovation. | Follow @JohnCFierce

@DamianFierce: In which the commissioner of the FDA reminds Americans that we have two very effective vaccines for measles. More | Follow @DamianFierce

> Regeneron says its allergy drug could be as big as PCSK9 blockers. Article

> Ahead of Novartis deal, GlaxoSmithKline scoops up vaccine developer in $190M buyout. Report

> MerLion becomes first home-grown Singapore firm to win U.S. FDA novel drug nod. Story

Pharma News

@FiercePharma: GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI: FDA puts off Mylan's Nexium generic, giving Teva's version free rein. Story | Follow @CarlyHFierce

> Glaxo's new meds are finally grabbing market share--but can they keep it up? Article

> Pfizer CEO thinks buys and swaps, with an eye toward future breakup. Story

> Can Valeant turn Dendreon's flailing Provenge into a viable cancer competitor? More

Drug Delivery News

> SteadyMed seeks $55M IPO to fund its drug delivery device, looks to upend United Therapeutics' Remodulin. Article

> The future: Biodegradable surgical tools to deliver drugs to remote parts of the body? Item

> UNC team uses electrical field to improve chemo delivery. Article

> Singapore team developing injectable glaucoma treatment, says noncompliance plagues eye drops. Story

> Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights. More

Diagnostics News

> Trovagene aims to raise $20M follow-on for urine-based cancer diagnostic. Report

> Japan's Quantum Biosystems raises $20M for next-gen DNA sequencer. News

> Roche scoops up Signature Diagnostics to gain ground in next-generation sequencing. Story

> Biocartis develops rapid Ebola triage test with Janssen Diagnostics. Item

> Myriad calls it quits on BRCA patent battle against Quest. Article

Pharma Marketing News

> Can Valeant transform Dendreon's ailing Provenge into a viable cancer competitor? Item

> Shire volleys with tennis star Seles to promote Vyvanse for binge eating. Report

> Patient groups still think ViiV is tops, with Novo and AbbVie close behind. Story

> Merck touches off Canadian controversy with Januvia doctor survey. Article

> Once again, Big Pharma's bad rep goes viral. Fair or not fair? More

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.